Foghorn Therapeutics(NASDAQ) FHTX

Foghorn Therapeutics Inc. makes medicines that help patients by controlling how their genes work. These treatments target specific genetic problems that cause cancer to grow. Its tools help scientists find new ways to stop serious diseases at their source.

How Foghorn Controls Genetic Traffic

• FHD-909: Selective inhibitor of the SMARCA2 protein used to treat cancer; currently in Phase 1 clinical development.
• Gene Traffic Control: Technology platform used to study how genes turn on and off; identifies new targets for drug discovery.
• SMARCA2 Degrader: Drug candidate designed to remove specific proteins involved in cancer growth; developed in partnership with Eli Lilly.
• Oncology Discovery Programs: Early research focusing on targets like ARID1B and CBP; aims to treat several types of solid tumors.

Strategic Alliances and New Capital

• Entered a collaboration agreement with Eli Lilly in December 2021 to develop oncology medicines.
• Received an upfront payment of $300.0 million from Eli Lilly in January 2022.
• Closed a $50.0 million stock and warrant offering on Jan. 13, 2026, to fund ongoing research.
• Transitioned the FHD-909 inhibitor program to Eli Lilly in the third quarter of 2023.
• Formed a research collaboration with Merck Sharp & MSD Corp. to discover new cancer therapies.

What Makes the Platform Different?

The company uses an integrated approach to study the chromatin regulatory system, which manages gene activity in human cells. By targeting this system, Foghorn aims to fix genetic errors found in approximately 50% of all cancers.

Performance by the Numbers

• Collaboration revenue was $19.3 million for the six-month period ended June 30, 2026.
• Net loss was $27.1 million for the six-month period ended June 30, 2026.
• Market cap was $344.7 million in Q2 2026, up 16.4% year over year.
• Cash, cash equivalents, and marketable securities totaled $167.6 million as of June 30, 2026.
• Accumulated deficit reached $659.5 million as of June 30, 2026.

Bottom Line

Foghorn has moved from early research to testing its most promising cancer drugs in human trials. By partnering with large pharmaceutical firms, the company combines its specialized genetic platform with the resources needed for global development.